Following the success of CoBRA 2015, CongressMed is pleased to announce that the 2nd World Congress on Controversies in Breast Cancer (CoBrCa) will be held in Barcelona, Spain on September 8 – 11, 2016 at the Hilton Barcelona.
CoBrCa will continue the tradition of directly addressing the key issues facing clinicians in their daily practice. More topics will be addressed. In addition to the key issues in medical oncology, surgery, radiation oncology and supportive care, CoBrCa will address controversial issues in radiology, pathology and reconstruction, with presentations, debates and discussions. The congress will again provide a forum to effectively debate unresolved clinical and therapeutic dilemmas.
- Screening and imaging
- Molecular profiling/pathology
- Locoregional management
- Neoadjuvant therapy
- Adjuvant systemic therapy
- Adjuvant endocrine therapy/fertility
- Management of advanced disease
- CNS metastases
- Future developments
Young Scientist Award
Who is eligible to enter?
Physicians, scientists & researchers born in 1982 or after
What is this competition all about?
The Scientific Committee of the 2nd World Congress on Controversies in Breast Cancer (CoBrCa) invites young scientists and researchers to submit their work and to join the Young Scientist Award competition.
The winner(s) will receive free registration, 3 nights hotel accommodation and the abstract will be presented as an oral presentation.
Wow! How do I enter? It’s very simple.
- Submit your abstract via the Congress website
- Register and pay registration fees (If your abstract is selected as a winner, your full registration fees will be refunded).
- Include your date of birth during the registration process.
Great! So what are the guidelines for submitting?
- Submitters must be born in 1982 or after.
- Submitters must be the first author of the abstract.
- Attendance at the Congress by the winner is mandatory in order to receive and collect the award.
- Winner(s) who cancel for any reason will not be entitled to collect their award.
- Richard De Boer, Australia
- Louis Chow, Hong kong
- Javier Cortes, Spain
- Giuseppe Curigliano, Italy
- Peter Dubsky, Austria
- Laura Esserman, USA
- Lesley Fallowfield, Canada
- Michael Gnant, Austria
- Katy Hogben, UK
- Kieran Horgan, UK
- Wolfgang Janni, Germany
- Stephen Johnston, UK
- Catherine Kelly, Ireland
- Michael Kerin, Ireland
- Bruce Mann, Australia
- Stacy Moulder, USA
- Seigo Nakamura, Japan
- Isabel Rubio, Spain
- Peter Schmid, UK
- Christos Sotiriou, Belgium
- Ash Subramanian, UK
- Alastair Thompson, USA
- Sunil Verma, Canada
- Sarah Vinnicombe, Scotland
Continuing Medical Education (CME) Accreditation
The 2nd World Congress on Controversies in Breast Cancer (CoBrCa), Barcelona, Spain, September 8 – 11, 2016 has been submitted for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME) – an institution of the European Union of Medical Specialists (UEMS).
The CME accreditation is valid for the main congress program only and does not cover the company-sponsored symposia.
For the Italian participants
The program for 2nd World Congress on Controversies in Breast Cancer (CoBrCa), Barcelona, Spain, September 8 – 11, 2016, will be submitted for CME accreditation from the Italian Ministry of Health.
ISO 9001 Certification
This Quality certification requires all participants to fill in a scientific questionnaire and to evaluate the overall quality of the event. Questionnaires will available online at the Congress website as at the conclusion of the congress for 3 weeks.
CME for USA participants
UEMS/EACCME CME credit recognition
The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS). Under the terms of this agreement, the AMA will convert CME credit certified by the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, to AMA PRA Category 1 Credit™.
Physicians (MDs, DOs or equivalent international degree) may have their EACCME credit converted to AMA PRA Category 1 Credit™ by applying to the AMA.
Educational needs and expected outcomes
- Assess and appraise controversial issues based on the latest findings by leading scientists in the field of breast cancer.
- Evaluate best practices in breast cancer.
- Discuss new scientific knowledge and recent research findings in the fields of neoadjuvant chemotherapy, breast screening and imaging, adjuvant endocrine therapy, controversies in breast reconstruction, controversies in advanced breast cancer.
- Recognize opportunities for scientific collaborations around the world.
- Integrate the most up to date information in their clinical and research activities.
- Evaluate the most important aspects of diagnosis and treatment of breast cancer.
- Presentations, discussions and debates will focus on the latest developments in breast cancer.
Disclosure of Conflicts of Interest (COI)
All declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided to the EACCME® upon submission of the application.
Declarations must include whether any fee, honorarium or arrangement for re-imbursement of expenses in relation to the event has been provided.
Industry support disclosure
We confirm that all funding provided is free of any attempt to influence the program, individual sessions, subjects for discussion, content or choice of faculty members conflicts of interest. Support of the Congress is kept in strict accordance with CME accreditation criteria.